Table 2.
Cardiovascular drugs in the study population
| Overall study population | Patients without CKD | Patients with CKD | P value | |
|---|---|---|---|---|
| (n = 463) | (n = 280) | (n = 183) | ||
| Angiotensin II receptor antagonists (%) | 33.3 | 34.3 | 33.1 | NS |
| ACE inhibitors (%) | 38.3 | 34.4 | 43.9 | 0.049 |
| Diuretics (%) | 38.8 | 37.7 | 42.7 | NS |
| Calcium antagonists | 39.4 | 42.5 | 37.2 | NS |
| β-blockers (%) | 15.3 | 16.7 | 12.3 | NS |
| αβ-blockers (%) | 10.7 | 12.3 | 9.4 | NS |
| α-blockers (%) | 32.4 | 24.6 | 46.8 | <0.001 |
| Centrally acting antiadrenergic drugs (%) | 6.8 | 5.6 | 9.4 | NS |
| Statins (%) | 16.4 | 17.1 | 16.3 | NS |
| Antiplatelet drugs (%) | 27.1 | 26.1 | 30.4 | NS |
| Allopurinol (%) | 8.2 | 4 | 11.7 | NS |
NS P > 0.05.
Abbreviations: CKD: chronic kidney disease.